

A Steady Flow Toward Approval



Key Potential Drug Launches in 2025


According to Biomedtracker’s Key Potential Drug Launches in 2025 report, the pipeline is set to deliver 69 key launches across 66 discrete drugs next year.* This is roughly the same number as predicted for 2024 back in July 2023.

*Data as of July 2024

Percentage of practice changing key potential drug launches

Just over half of the key launches forecast for 2025 have the potential to change disease treatment practices.

These include LIB Therapeutics’ lerodalcibep, an injectable recombinant fusion protein that could transform treatment for dyslipidemia and hypercholesterolemia; and CagriSema, another game-changing obesity treatment from Novo Nordisk.




Source: Biomedtracker, July 2024

Key potential drug launches in 2025 by therapeutic area

Oncology remains the leading therapeutic category in terms of key potential launches, with 19 on the cusp of approval in 2025.

This includes five label expansions of existing products, such as Karyopharm Therapeutics’ expanding multiple myeloma therapy Xpovio to treat endometrial cancer; and four products that belong to a new drug class, including the first-in-class menin inhibitor revumenib being developed by Syndax Pharmaceuticals for acute myeloid leukemia.



Source: Biomedtracker, July 2024

Molecule type of key potential drug launches in 2025

Close to half of next year’s total potential drug launches are small-molecule drugs, while monoclonal antibodies represent roughly one-fifth of the total.

The “other” category includes Gritstone bio’s GRANITE, a personalized neoantigen-based vaccine for colorectal cancer; and Capricor’s deramiocel, an allogenic cardiosphere-derived cell therapy for Duchenne muscular dystrophy.



Source: Biomedtracker, July 2024

About Biomedtracker

Biomedtracker is your essential platform for real-time insights into commercial, clinical, and regulatory activities. It offers a comprehensive view of the drug development landscape, providing up-to-the-minute tracking of key events, catalysts, and deals.

[FIND OUT MORE](#)

To learn more about the advantages we can deliver to your company, please visit: [Citeline.com](https://www.citeline.com) or email: info@citeline.com